
    
      This is a dose escalation study by design, allowing the assessment of safety, tolerability
      and recommended dose levels of the combination of T-DXd and durvalumab plus cisplatin,
      carboplatin or pemetrexed. Expansions on any recommended dose level may take place to study
      preliminary efficacy as well.

      The target population of interest are patients with advanced or metastatic non-small cell
      lung cancer and HER2 overexpression who are treatment na√Øve and have measurable disease by
      RECIST criteria and ECOG PS of 0 to 1.
    
  